Urogen Pharma Ltd - ESG Rating & Company Profile powered by AI
This Disclosure score covers 17 United Nations Sustainable Development Goals including: 'Affordable & Clean Energy', 'Reduced Inequalities' and 'Life below Water'. If you work at Urogen Pharma Ltd and you wish to use your ESG aseessment, please contact us. This analysis of Urogen Pharma Ltd was prepared by All Street Sevva using proprietary machine learning.
Urogen Pharma Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.5; made up of an environmental score of 4.0, social score of 6.4 and governance score of 3.2.
4.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 852 | Vaccibody AS | 4.6 | High |
| 852 | argenx SE | 4.6 | High |
| 868 | Urogen Pharma Ltd | 4.5 | High |
| 868 | CARsgen Therapeutics Holdings Ltd | 4.5 | High |
| 868 | Boiron SA | 4.5 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Urogen Pharma Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Urogen Pharma Ltd report the average age of the workforce?
Sign up for free to unlockDoes Urogen Pharma Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Urogen Pharma Ltd offer flexible work?
Sign up for free to unlockDoes Urogen Pharma Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Urogen Pharma Ltd conduct supply chain audits?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Urogen Pharma Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose water use targets?
Sign up for free to unlockDoes Urogen Pharma Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Urogen Pharma Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Urogen Pharma Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Urogen Pharma Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Urogen Pharma Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Urogen Pharma Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Urogen Pharma Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose its waste policy?
Sign up for free to unlockDoes Urogen Pharma Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose energy use targets?
Sign up for free to unlockDoes Urogen Pharma Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Urogen Pharma Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Urogen Pharma Ltd
These potential risks are based on the size, segment and geographies of the company.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.